AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 APR 10 - (NewsRx.com & NewsRx.net) -- The German-American biopharmaceutical company MediGene AG (MDG) announced that the U.S. patent office has issued U.S. patent No. 6,352,696, "Papillomavirus truncated L1 protein and fusion protein constructs" regarding vaccines to treat tumors induced by human papilloma virus infections (HPV infections).
The patent protects specific DNA constructs used to produce the vaccine particles as well as the manufacturing process. MediGene is developing such a vaccine for the treatment of cervical cancer and its precursors, which is currently undergoing phase I/II clinical trials.
"This patent will fundamentally strengthen our ...